Media ReleasesImmutep

View All Immutep News

Immutep announces Webcast to discuss IMP761 preclinical results

Immutep to Present IMP761 Preclinical Results in Global Webcast

SYDNEY, AUSTRALIA – March 19, 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, advises that its Chief Medical Officer and Chief Scientific Officer, Dr. Frédéric Triebel, and its Chief Executive Officer, Marc Voigt will present preclinical results of IMP761 in a global webcast.

IMP761 is a novel LAG-3 agonist antibody being developed for the treatment of autoimmune diseases. The results were presented at the 14th Congress of European Crohn’s and Colitis Organisation (ECCO) Conference in Denmark on 7 March 2019.

At the site of chronic inflammation, autoimmune memory T cells are stimulated by the same self-peptides repeatedly, acquiring an “exhausted” phenotype. Immutep used LAG-3, a marker for exhausted memory T cells, to target these self-reactive T cells in vivo. As LAG-3 is a T cell co-inhibitory receptor, the Company has developed an agonist antibody, IMP761, to increase LAG-3 down-modulation of T cell receptor signaling in these autoimmune T cells.

For further information please download PDF attached: 
Download this document